Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™)

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung


  • Tjalf Ziemssen - , Klinik und Poliklinik für Neurologie (Autor:in)
  • Lauren Sylvester - , Bayer AG (Autor:in)
  • Mark Rametta - , Bayer AG (Autor:in)
  • Amy Perrin Ross - , Loyola University Chicago (Autor:in)


Introduction: Multiple sclerosis (MS) typically requires life-long management with disease-modifying therapies (DMTs). Many DMTs require regular self-injection, and can be associated with injection site reactions, pain, and needle/injection phobia—but these can be addressed by improvements in autoinjector design. The aim of this study was to investigate patient satisfaction and preference for BETACONNECT™ (Bayer Pharma AG), a novel interferon beta-1b autoinjector. Methods: Patients in Germany performing self-injections using BETACONNECT took part in the study. Data were collected through an online 15-min structured survey. Participants rated their experience with BETACONNECT on a 6-point scale and those satisfied with BETACONNECT were asked to describe the reason using a free-text box. Results: One-hundred and eighteen patients with MS completed the survey. Ninety percent preferred BETACONNECT to their previous injection method (only 4% previously used manual injections, so most had previously used other autoinjectors). Ninety-two percent were very confident/confident in their ability to perform an injection using BETACONNECT. The most common free-text responses to “Why are you satisfied with the BETACONNECT™ autoinjector?” were ease of use (46%), less irritation/pain at the injection site (33%), and smoother injections (24%). Features considered most useful were automated injections (98%), adjustable injection speed (98%), and adjustable injection depth (98%). Ninety-seven percent thought it was easy to know when an injection was complete and 95% agreed/strongly agreed it was easy to learn to use the autoinjector. Seventy-three percent agreed that the quietness and effortlessness of the BETACONNECT reduced their level of injection anxiety, 92% that its size and shape makes it easy to handle during injections, and 67% that it decreases injection site pain. Eighty percent of those using the reminder function thought they were less likely to miss an injection. Conclusion: Patients with MS self-injecting interferon beta-1b expressed a high level of satisfaction and preference for BETACONNECT. Thus, BETACONNECT represents a valid option to improve patients’ overall injection experience. Funding: Bayer HealthCare Pharmaceuticals.


Seiten (von - bis)125-136
FachzeitschriftNeurology and Therapy
PublikationsstatusVeröffentlicht - 1 Dez. 2015


ASJC Scopus Sachgebiete


  • Beta-interferons, Disease-modifying therapies, Electronic autoinjector, Patient survey, Relapsing–remitting multiple sclerosis